(RTTNews) - Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. The study focuses on: development and optimization ...

With May the Fourth waiting in the (Starfighter) wings, do keep your eyes peeled for all the new Star Wars releases at Disney Store — after all, to quote our favorite green Jedi Grand Master, when it ...

Hoth Therapeutics (HOTH) responded to recent market rumors and inquiries from shareholders regarding its financial plans and ongoing clinical trials. The company affirms that it has no plans for a ...

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company ...

HT-KIT triggered significant tumor cell death in preclinical models of gastrointestinal stromal tumors (GIST) and systemic mastocytosis as early as 24 hours post-treatment, with statistically ...

Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism. Processing and qualitative evaluation of tissue samples by a board-certified ...

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to ...

NEW YORK, Oct. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for dermatological, oncology ...